Drugs & Aging

, Volume 30, Issue 12, pp 979–986 | Cite as

Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies

  • Marguerite Vignon
  • Marie-Dominique Venon
  • Olivier Hermine
  • Richard Delarue
Review Article


Mantle cell lymphoma is a distinct subtype of B-cell non-Hodgkin lymphoma, accounting for 3–10 % of all non-Hodgkin lymphoma cases. The median age at diagnosis is nearly 70 years. The prognosis of patients is based on the Mantle Cell Lymphoma International Prognostic Index, which is calculated on the basis of four independent prognostic factors (age, performance status, serum lactate dehydrogenase and leukocyte count). Treatment of elderly patients with de novo untreated mantle cell lymphoma is based on rituximab combined with chemotherapy. The most commonly used regimen is the classical CHOP21 (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen. Bendamustine is also an option, especially for patients with cardiac comorbidities. In elderly patients who are relatively young and fit, an approach based on treatment usually used for younger patients, with cytarabine-based induction followed by autologous stem cell transplantation, should be discussed. Treatment of relapsing patients is based on the use of newer effective drugs, including bortezomib, lenalidomide and thalidomide, and mammalian target of rapamycin (mTOR) inhibitors, such as temsirolimus. These drugs are often combined with rituximab and can be prescribed in combination with chemotherapy. Promising new drugs are Bruton tyrosine kinase inhibitors and other inhibitors of the phosphoinositide 3-kinase (PI3K)–mTOR–protein kinase B (AKT) pathway. Despite these new advances, mantle cell lymphoma remains an incurable disease, and further basic and clinical research is warranted.


Funding and Conflict of Interest Disclosure Statements

There was no funding for the preparation of this manuscript. Marguerite Vignon and Marie-Dominique Venon have no conflicts of interest to declare. Olivier Hermine has received consulting fees or honoraria from Celgene, Johnson & Johnson, Roche and Pfizer; support for travel to meetings for the study, manuscript preparation or other purposes from Celgene and Roche; and payment for lectures, including service on speakers’ bureaus from Johnson & Johnson. Richard Delarue has received payment for lectures from Sandoz, Roche, Pfizer and Celgene. He served as a member of a data and safety monitoring board of a study sponsored by Millenium. He has also received travel support from Celgene, Novartis, Roche and Mundipharma.


  1. 1.
    Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21:293–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Swerdlow AJ, Campo E, Harris ES, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: France IARC Press; 2008.Google Scholar
  3. 3.
    Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111:5683–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Thieblemont C, Rolland D, Baseggio L, et al. Comprehensive analysis of GST-π expression in B-cell lymphomas: correlation with histological subtypes and survival. Leuk Lymphoma. 2008;49:1403–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012;87:604–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Swerdlow SH, Habeshaw JA, Murray LJ, et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol. 1983;113:181–97.PubMedGoogle Scholar
  9. 9.
    Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS Group. Eur J Nucl Med Mol Imaging. 2010;37:1633–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Martin P, Leonard J. Is there a role for “watch and wait” in patients with mantle cell lymphoma? Semin Hematol. 2011;48:189–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119:4215–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Ghielmini M, Schmitz SFH, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013. doi:10.1016/S0140-6736(12)61763-2.
  24. 24.
    Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16:587–93.PubMedCrossRefGoogle Scholar
  25. 25.
    Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000;39:77–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts). 2012;120:151.Google Scholar
  28. 28.
    Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–9.Google Scholar
  29. 29.
    Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2010;377:42–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith MR, Li H, Gordon L, Gascoyne RD, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90–ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30:3119–26.PubMedCrossRefGoogle Scholar
  33. 33.
    Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol. 2011;48:208–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Houot R, Gouill SL, Uribe MO, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012;23:1555–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol. 2006;7:285–94.PubMedCrossRefGoogle Scholar
  41. 41.
    Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12:361–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97:1085–91.PubMedCrossRefGoogle Scholar
  44. 44.
    Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21:15–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23:147–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Wang M, Rule SA, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.Google Scholar
  47. 47.
    Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol. 2012;25:185–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Damaj G, Lefrere F, Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17:1914–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104:2269–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–95.Google Scholar
  51. 51.
    Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–23.PubMedCrossRefGoogle Scholar
  52. 52.
    Hamaker ME, Jonker JM, De Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13:e437–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Marguerite Vignon
    • 1
  • Marie-Dominique Venon
    • 1
  • Olivier Hermine
    • 1
    • 2
  • Richard Delarue
    • 1
    • 2
  1. 1.Service d’Hématologie AdultesAP-HP, Hôpital NeckerParis Cedex 15France
  2. 2.Institut ImagineUniversité Sorbonne Paris CitéParisFrance

Personalised recommendations